Observational studyEuropean journal of pediatrics2026
Rate and timing to clinical remission in celiac children on a gluten-free diet.
Observational study in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This observational retrospective study describes the rate and time of symptom resolution in celiac disease (CD) in a cohort of pediatric patients following a gluten-free diet (GFD). We evaluated the rate and time to symptom resolution after starting a GFD, as well as associated predictive factors (age, gender, comorbidities, familial history, IgA anti-transglutaminase antibodies (TGA-IgA) at diagnosis, dietary adherence), in children diagnosed with CD between 2014 and 2022 at the Gastroenterology Unit of Maggiore Hospital, Bologna. The minimum follow-up period was 6 months. Of 421 symptomatic patients at diagnosis, 77.4% presented gastrointestinal symptoms (GIs) (40.6% recurrent abdominal pain, 19.5% diarrhea, 21.6% constipation, 17.3% bloating), 47.5% extra-intestinal symptoms (EISs) (16.4% neurological symptoms, 9.0% anemia), and 33.5% growth retardation (31.6% failure to thrive, 17.8% short stature). 96.7% had a high GFD adherence through follow-up. The overall symptom resolution rate was 84.8% (GIs 89.0%, EISs 92.6%, growth retardation 87.4%). Constipation had a significantly lower resolution rate compared to other GIs (p = 0.02) or diarrhea (p = 0.03). In total, 81.7% of patients achieved symptom resolution within 12 months. Short stature and anemia resolved more slowly compared to other symptoms. TGA-IgA normalization and GFD adherence were significant predictors of symptom resolution.
conclusionMost symptoms resolved within the first year of diagnosis. The lower resolution rate for constipation compared to other GIs suggests a functional etiology, while the delayed recovery of anemia and short stature likely reflects their complex etiology. Serological normalization and GFD adherence are confirmed as predictors of clinical remission. WHAT IS KNOWN: • Time to clinical remission in celiac children after starting a gluten-free diet may vary between different symptoms. • Clinical remission is associated with serological normalization and adherence to diet. WHAT IS NEW: • Constipation has a significantly poorer rate of resolution among other gastrointestinal symptoms, due to its functional etiology, while anemia and short stature resolve slightly slower. • Most patients reach clinical remission within the first year on a gluten-free diet; serological normalization and diet adherence are confirmed to be predictors of clinical remission.
Indexed as
Identifiers
42103965What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.